Several laboratories worldwide established molecular detection of MERS-CoV by reverse transcriptase polymerase chain reaction (RT-PCR) early in the outbreak. WHO encouraged these laboratories to provide technical support and reference testing service to countries without such capacity while expanding MERS-CoV testing at the national level by building primarily on the existing molecular testing capacity of the Global Influenza Surveillance and Response System (GISRS). Serological assays for MERS-CoV have also been developed, but they are not widely available and have not been fully validated; case confirmation has relied predominantly on molecular detection methods.
We present the findings of a voluntary, rapid survey targeting national-level public health laboratories in the Western Pacific Region. The survey was administered after nearly two years of activities aimed at building laboratory capacity for MERS-CoV detection and sought to determine preparedness of countries for MERS-CoV testing. Questions addressed three main areas: availability of protocols, guidance and reagents; immediate testing capacity; and referral mechanisms.
The survey was web-based, consisted of 21 multiple-choice questions and was conducted between 18 June and 14 July 2014. Participating laboratories were assured of confidentiality and the reproduction of aggregated data alone in publications. A total of 21 survey invitations were distributed to 18 countries and areas (areas 4 are non-sovereign jurisdictions within a WHO region, such as the French overseas collectivities of New Caledonia and French Polynesia; countries and areas are together referred to as "countries" in this article). Invitations principally targeted one responsible laboratory in each country; for three countries, two laboratories were included as they were both tasked with MERS-CoV testing. Survey responses were not verified for accuracy.
Results are illustrated in Table 1 . The survey was completed by 19 laboratories in 16 countries of the Western Pacific Region. The majority of participating laboratories (15/19) were National Influenza Centres (NICs) or located within an institution housing an NIC, highlighting the role of the pre-existing GISRS network in MERS-CoV testing.
Sixteen (84.2%) laboratories in 13 countries indicated that they had capacity in place for molecular detection of MERS-CoV, while three laboratories used referral mechanisms instead. All 16 laboratories with MERS-CoV testing capacity responded that they had a standard operating procedure for molecular detection of MERS-CoV in place, with 12 choosing to incorporate Squires and Konings MERS-CoV testing preparedness in the Western Pacific Region the Region. To determine each laboratory's emergency outbreak capacity, participants were also asked to estimate the volume of suspected MERS-CoV samples that could be processed in 48 hours. Of the 16 laboratories with MERS-CoV testing capacity, three (18.8%) indicated they could test over 250 samples, five (31.2%) could test 50-250 samples and eight (50%) could test 1-50 samples. Two-thirds (11) of these laboratories maintained that they could report to public health authorities within one day of obtaining results; the remainder could report in 2-5 days.
Referral is an important mechanism for pathogen identification and confirmation. Of the 19 laboratories participating in the survey, five (two in low-income and three in high-income countries) 8 At the time of the survey, 10 laboratories in nine Western Pacific Region countries had already tested suspected samples of MERS-CoV, indicating the importance of testing capacity in the Region even though the virus thus far primarily affects countries outside The findings of this survey revealed good regional laboratory coverage in the Western Pacific Region for molecular detection of MERS-CoV, primarily through the GISRS laboratory network, nearly two years after the first reported MERS-CoV case in the Middle East. All countries indicated that they had national-level laboratories with the necessary materials for MERS-CoV testing on-site or employed international referral. It is important to continue strengthening the apparatus for MERS-CoV detection in the Region, in particular ensuring testing proficiency by EQA participation, and enhancing referral mechanisms and IATA certification where needed. National-level capacity is a key asset provided that it is well connected with the public health system at the subnational level. In-country referral capacity must therefore also be in place. WHO and its partners will continue to provide technical support to countries to address these issues. In conclusion, while there proved to be sufficient time to build laboratory capacity for the detection of MERS-CoV before its entry into the Western Pacific Region, we may not be so fortunate for future emerging infectious diseases. Thus, maintaining and further strengthening the public health laboratory system is a critical undertaking.
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